



Post Authorisation Assessments

Cefaseptin 300 mg Tablets for Dogs

Vm 08007/4142

•	18 May 2024	Editorial change to part 2 of the dossier.
•	21 December 2023	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV). Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex. (NI)
•	03 February 2021	Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer.
•	02 February 2021	Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer.
•	24 November 2020	Renewal - UK as CMS.
•	24 December 2019	Increase in the shelf-life of the finished product as packaged for sale, from 2 years to 3 years.
•	20 March 2019	Change in RMS from UK to FR
•	31 January 2019	Minor changes to an approved test procedure of the finished product.
•	25 January 2019	Change in the address of the marketing authorisation holder from VETOQUINOL Österreich GmbH, Zehetnergasse 24, 1140 Wien to Vetoquinol Österreich GmbH, Gußhausstraße 14/5, 1040 Wien in AT.
•	07 September 2018	Change in the address of the marketing authorisation holder from Vétoquinol UK Limited, Vetoquinol House, Great Slade, Buckingham Industrial Park, Buckingham, MK18 1PA to Vetoquinol UK Limited, Steadings Barn, Pury Hill Business Park, Nr Alderton, Towcester, Northamptonshire, NN12 7LS.
•	04 December 2017	Minor changes to an approved test procedure of the finished product.
•	30 August 2017	Change in the address of the marketing authorisation holder in Germany from Vetoquinol GmbH, Parkstr. 10, D - 88212 Ravensburg to Vetoquinol GmbH, Reichenbachstr. 1, D-85737 Ismaning.
•	23 March 2016	Change in Product Name in France, Denmark and Slovenia